IJU Case Reports (Sep 2022)

Deterioration of bladder compliance after botulinum toxin A injection and discontinuation of medication for overactive bladder

  • Naoki Wada,
  • Mayumi Ishikawa,
  • Masaya Nagabuchi,
  • Shogo Makino,
  • Kotona Miyauchi,
  • Noriyuki Abe,
  • Hidehiro Kakizaki

DOI
https://doi.org/10.1002/iju5.12496
Journal volume & issue
Vol. 5, no. 5
pp. 384 – 388

Abstract

Read online

Introduction We report a case of deterioration of bladder compliance after botulinum toxin type A injection and discontinuation of medication for overactive bladder. Case presentation A female patient with overactive bladder in her sixties had been visiting our outpatient clinic regularly for 4 years. She had received posterolateral spondylus fusion twice, which resulted in a compression fracture. She had been receiving a combination therapy of anticholinergics and β3‐adrenoceptor agonist for the management of overactive bladder. She received botulinum toxin type A injection for refractory overactive bladder and discontinued medical treatment for overactive bladder. Three months after botulinum toxin type A injection, cystometry revealed the deterioration of bladder compliance. Renal dysfunction, hydronephrosis, and vesicoureteral reflux were shown. Renal function and hydronephrosis were improved after restarting anticholinergics and β3‐adrenoceptor agonist therapy and inserting a temporary transurethral catheter. Conclusion Deterioration of bladder compliance may occur after botulinum toxin type A injection and discontinuation of overactive bladder medication in some patients with underlying neurological disease.

Keywords